Results 11 to 20 of about 3,049 (238)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia [PDF]

Lipids in Health and Disease, 2011
Background Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between inflammation and cardiovascular disease, and thus is a suitable target for therapeutic strategy against cardiovascular disease.
Minichilli Fabrizio, Bigazzi Federico, Sbrana Francesco, Puntoni Mariarita, Ferdeghini Ezio, Sampietro Tiziana   +5 more
doaj   +6 more sources

Management of Severe Hypertriglyceridemia in Pregnancy With Niacin: Reevaluating Safety and Therapeutic Benefits. [PDF]

Case Rep Endocrinol
Background: Severe hypertriglyceridemia (triglycerides (TGs) >1000 mg/dL, >11.3 mmol/L) is a rare but potentially morbid condition in pregnancy. Physiological changes in pregnancy may unmask or exacerbate an underlying defect in TG metabolism. When conventional therapies are ineffective in controlling TG levels, a personalized management approach is ...
Suda N, Leon-Martinez D, Peter PR, Flannery CA, Irani RA.   +4 more
europepmc   +2 more sources

Functional characteristics of LDL particles derived from various LDL-apheresis techniques regarding LDL-drug-complex preparation.

Journal of Lipid Research, 1990
Low density lipoproteins (LDL) have the potential to serve as cell specific drug carriers. The LDL may be derived in large quantities from LDL-apheresis procedures.
HW Schultis, H von Baeyer, H Neitzel, E Riedel   +3 more
doaj   +2 more sources

LDL Apheresis and Lp (a) Apheresis: A Clinician's Perspective. [PDF]

Curr Atheroscler Rep, 2021
Lipoprotein apheresis is the most effective means of lipid-lowering therapy. However, it's a semi-invasive, time consuming, and chronic therapy with variable adherence. There are still no specific guideline recommendations for the management of patients on lipid apheresis.
Kayikcioglu M.
europepmc   +6 more sources

Early-onset familial hypercholesterolemia: A case of extensive xanthomas and premature coronary artery disease. [PDF]

Clin Case Rep
Key Clinical Message Early recognition and management of familial hypercholesterolemia (FH) are crucial, especially in patients with extensive xanthomas and premature coronary artery disease. Prompt diagnosis and aggressive lipid‐lowering therapy can significantly reduce morbidity and mortality rates.
Kalsi H, Singla A, Kaur S, Verma A, Woldehana NA, Rustagi S, Singh MP.   +6 more
europepmc   +2 more sources

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia. [PDF]

Lipids Health Dis, 2016
Varga VE, Lőrincz H, Zsíros N, Fülöp P, Seres I, Paragh G, Balla J, Harangi M.   +7 more
europepmc   +3 more sources

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late. [PDF]

Arch Med Sci, 2015
Mickiewicz A, Fijałkowski M, Rynkiewicz A, Raczak G, Gruchała M.   +4 more
europepmc   +3 more sources

Long-term effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia: an observational case series [PDF]

Orphanet Journal of Rare Diseases
Background We assessed long-term real-world effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia (HoFH). Methods Retrospective case series of six patients with HoFH treated with lomitapide in an Italian clinic.
Patrizia Suppressa, Chiara Coppola, Veronica Cocco, Sallyann O’Brien   +3 more
doaj   +2 more sources

A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome. [PDF]

Nephron Extra, 2015
Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Takemura T, Yuzawa Y, Ogahara S, Sugiyama S, Iino Y, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Imai E, Matsuo S, Saito T.   +23 more
europepmc   +3 more sources

Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia

Journal of Lipid Research, 1996
Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is, however, unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates,
K G Parhofer, P H Barrett, T Demant, W O Richter, P Schwandt   +4 more
doaj   +2 more sources